Search company, investor...

Flexible Medical Systems

Founded Year



Angel - IV | Alive

Total Raised


Last Raised

$300K | 10 yrs ago

About Flexible Medical Systems

Flexible Medical Systems is a medical diagnostics and devices company focused on remote transdermal biomonitoring systems for the human body as well as animal applications, and developing new standards in the emergent connected healthcare market.

Headquarters Location

15601 Crabbs Branch Road

Rockville, Maryland, 20855,

United States


Missing: Flexible Medical Systems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Flexible Medical Systems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Flexible Medical Systems Patents

Flexible Medical Systems has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Diabetes, Analytical chemistry, Male suicides, Molecular biology, Biotechnology


Application Date


Grant Date



Related Topics

Diabetes, Analytical chemistry, Male suicides, Molecular biology, Biotechnology



Flexible Medical Systems Frequently Asked Questions (FAQ)

  • When was Flexible Medical Systems founded?

    Flexible Medical Systems was founded in 2005.

  • Where is Flexible Medical Systems's headquarters?

    Flexible Medical Systems's headquarters is located at 15601 Crabbs Branch Road, Rockville.

  • What is Flexible Medical Systems's latest funding round?

    Flexible Medical Systems's latest funding round is Angel - IV.

  • How much did Flexible Medical Systems raise?

    Flexible Medical Systems raised a total of $3.24M.

  • Who are Flexible Medical Systems's competitors?

    Competitors of Flexible Medical Systems include Axion BioSystems, Integrated Nano-Technologies, iMMCO Diagnostics, Median Technologies, Cardiac Science Corporation and 12 more.

Compare Flexible Medical Systems to Competitors


Nervonix, Inc. is a medical device company that has invented, patented, and prototyped a break-through nerve imaging technology that operates non-invasively at the skin surface to accurately locate and image peripheral nerves.

Interventional Imaging

Interventional Imaging Inc. (I3) is a medical device company focused on the detection and treatment of vulnerable plaque in the coronary arteries of the heart. I3 was formed by Case Western Reserve University and is based on technologies developed in the Department of Radiology at University Hospitals of Cleveland.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.


ActiViews is engaged in developing multidisciplinary medical device. It develops a guiding system for interventional radiology procedures, initially for biopsy diagnosis. Activiews' system combines a sensor and a software package to enable simple, safe and accurate procedure. ActiViews' products aim to improve current procedures performed under CT (and other modalities in the future) through improvement of patient safety, reducing total time for procedure and potentially improving accuracy. At a later stage, the system will be integrated in imaging modalities to perform highly-focused radiation of carcinogenic tumors.

LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

Cellpoint Diagnostics

CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.